Icotyde (oral IL-23) FDA approval — competitive threat to Skyrizi
Key Questions
What is Icotyde and when was it FDA approved?
Icotyde is an oral IL-23 inhibitor developed by Protagonist Therapeutics and J&J. It received FDA approval on March 18 based on Ph3 ICONIC trial data. A Q2 launch is planned with an adherence advantage over injectables.
How does Icotyde pose a competitive threat to Skyrizi?
Icotyde targets the same IL-23 pathway as AbbVie's Skyrizi for psoriasis but offers oral administration for better adherence. BMO projects peak sales of $3.2B. This could erode Skyrizi's market share in the IL-23 class.
How is AbbVie responding to the Icotyde approval?
AbbVie is countering with the acquisition of Nimble Therapeutics, gaining a preclinical oral peptide IL-23R inhibitor for psoriasis. This positions AbbVie to compete in the oral IL-23 space long-term. Nimble's asset is investigational and in preclinical development.
FDA approved Mar18 Ph3 ICONIC (Prot/J&J); adherence edge; BMO $3.2B peak; Q2 launch. ABBV Nimble preclinical oral peptide IL-23R acq counter.